Sutureless transconjunctival 20 g pars plana vitrectomy

Article

Sutureless transconjunctival 20 g ppv is, according to this study, an ideal technique for all vitreoretinal surgeries.

Key Points

Minimally invasive techniques have been introduced across virtually the whole spectrum of surgery. In ophthalmology sutureless operating techniques in cataract surgery and recently in vitrectomy offer less postoperative inflammation, shorter intraoperative and recovery time. In this article is reported the evaluation, feasibility and safety of the Sutureless Transconjuctival 20 Gauge Vitrectomy (20 STV).

How the technique works

Subconjunctival antibiotics and corticosteroids are used at the end of the procedure. Few fluid filled eyes had minimal leakage of fluid. Eyes with air or gas fill are less likely to be hypotonous at the end of theoperation. Eyes that ended up with silicone oil had no leakage at all due to higher viscosity of the oil. The pressure of the eyes at the end of the operation was either normal or slightly low. In cases where hypotony was noticed additional air or fluid was injected through pars plana with a 27 gauge needle. Slight chemosis occurred in a few cases.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.